Most-Downgraded StocksMost-DowngradedNASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $674.27 +10.41 (+1.57%) Closing price 02/13/2025 04:00 PM EasternExtended Trading$671.50 -2.77 (-0.41%) As of 02/13/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Regeneron Pharmaceuticals Stock (NASDAQ:REGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get REGN alerts:Sign Up Key Stats Today's Range$661.94▼$677.6950-Day Range$663.86▼$788.0052-Week Range$642.00▼$1,211.20Volume604,705 shsAverage Volume978,359 shsMarket Capitalization$74.10 billionP/E Ratio17.61Dividend YieldN/APrice Target$973.13Consensus RatingModerate Buy Company OverviewRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More… Regeneron Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks99th Percentile Overall ScoreREGN MarketRank™: Regeneron Pharmaceuticals scored higher than 99% of companies evaluated by MarketBeat, and ranked 43rd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 16 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth21.63% Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 21.63% in the coming year, from $36.67 to $44.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 17.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.20.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 17.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.10.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.99% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 3.30%, indicating that investor sentiment is decreasing. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Regeneron Pharmaceuticals is 2.30%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 1.97% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.Read more about Regeneron Pharmaceuticals' dividend. Sustainability and ESG2.3 / 5Environmental Score-2.69 Percentage of Shares Shorted1.99% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 3.30%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment0.37 News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 66 news articles for Regeneron Pharmaceuticals this week, compared to 22 articles on an average week.Search Interest44 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows29 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 81% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.48% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Stock News HeadlinesBillions in Buybacks: 4 Stocks Rewarding Shareholders Now (REGN)These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.February 6, 2025 | marketbeat.comRegeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGNFebruary 14 at 5:45 AM | prnewswire.comElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.February 14, 2025 | True Market Insiders (Ad)March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGNFebruary 13 at 12:39 PM | globenewswire.comThe Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGNFebruary 13 at 5:45 AM | prnewswire.comAnalyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens BermanFebruary 12 at 6:57 PM | globenewswire.comFMR LLC Reduces Stake in Regeneron Pharmaceuticals IncFebruary 12 at 2:13 PM | gurufocus.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) ShareholdersFebruary 12 at 12:55 PM | globenewswire.comSee More Headlines REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $712.33 at the beginning of the year. Since then, REGN stock has decreased by 5.3% and is now trading at $674.27. View the best growth stocks for 2025 here. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings results on Tuesday, February, 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. Read the conference call transcript. Does Regeneron Pharmaceuticals have any subsidiaries? Regeneron Pharmaceuticals subsidiaries include Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and others. Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' top institutional shareholders include Vanguard Group Inc. (8.45%), FMR LLC (7.46%), Geode Capital Management LLC (2.21%) and Dodge & Cox (2.11%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi, N Anthony Coles and George L Sing. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings2/04/2025Today2/14/2025Ex-Dividend for 3/20 Dividend2/20/2025Dividend Payable3/20/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$973.13 High Stock Price Target$1,300.00 Low Stock Price Target$165.00 Potential Upside/Downside+44.3%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage25 Analysts Profitability EPS (Most Recent Fiscal Year)$38.28 Trailing P/E Ratio17.61 Forward P/E Ratio18.39 P/E Growth2.38Net Income$3.95 billion Net Margins31.07% Pretax Margin33.66% Return on Equity16.32% Return on Assets12.76% Debt Debt-to-Equity Ratio0.09 Current Ratio4.73 Quick Ratio4.46 Sales & Book Value Annual Sales$14.20 billion Price / Sales5.22 Cash Flow$42.46 per share Price / Cash Flow15.88 Book Value$267.12 per share Price / Book2.52Miscellaneous Outstanding Shares109,890,000Free Float101,670,000Market Cap$74.10 billion OptionableOptionable Beta0.08 Social Links 7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:REGN) was last updated on 2/14/2025 by MarketBeat.com Staff From Our Partners*Breaking News!* This Pharma NASDAQ Company and the U.S Army!!! This Little Known NASDAQ Company just released positive results from its drugs that have been undergoing testi...Trading Wire | Sponsored[RFK Jr CONFIRMED] But Will THIS Be His DownfallRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s #1 investment during Trump’s termWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredElon has entered the MarkBeat conversationSpivey's firm accurately warned of both the 2008 and 2020 stock market crashes and have charged institutional ...Altimetry | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredJUST RELEASED: HUGE NEW A.I. TRADEI’ve traded every major tech boom since the dawn of the personal computer. And I can tell you one thing wit...The Oxford Club | SponsoredFrom bankrupt to delivering 610,000% returnsWalk the empty streets of this barren town and you would have no idea that behind the sand-scarred blight is o...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.